<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): September 23, 1998
Nitinol Medical Technologies, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-21001 95-4090463
- ------------------------ -----------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
27 Wormwood Street, Boston, MA 02210
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(617) 737-0930
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
Not Applicable
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
ITEM 5. OTHER EVENTS.
On September 23, 1998, Nitinol Medical Technologies, Inc. (the
"Corporation") issued a press release regarding the naming of William J. Knight
as Vice President of Finance and Administration and Chief Financial Officer of
the Corporation. A copy of this press release is attached as an exhibit to this
Form 8-K and is incorporated herein by reference.
-2-
<PAGE>
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits:
Exhibit Number Description
- -------------- -----------
99.1 Press Release dated September 23, 1998.
-3-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NITINOL MEDICAL TECHNOLOGIES, INC.
Dated: September 29, 1998 By: /s/ Thomas M. Tully
--------------------------
Name: Thomas M. Tully
Title: President, Chief Executive Officer
-4-
<PAGE>
INDEX TO EXHIBITS
Exhibit Number Description
- -------------- -----------
99.1 Press Release dated September 23, 1998.
<PAGE>
NEWS BULLETIN
NITINOL MEDICAL TECHNOLOGIES, INC.
FROM: 27 Wormwood Street
FRB Boston, MA 02210-1625
(Nasdaq/NMS:NMTI)
- --------------------------------------------------------------------------------
The Financial Relations Board, Inc.
FOR FURTHER INFORMATION:
AT THE COMPANY: AT THE FINANCIAL RELATIONS BOARD
-------------- --------------------------------
Thomas M. Tully General Info: Paul Henning (212) 661-8030
President & CEO Analyst Info: Brian Gill (212) 661-8030
(617) 737-0930 Media Info: Deanne Eagle (212) 661-8030
FOR IMMEDIATE RELEASE
---------------------
September 23, 1998
NITINOL MEDICAL TECHNOLOGIES, INC. NAMES WILLIAM J. KNIGHT
----------------------------------------------------------
VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
------------------------------------------
Boston, MA, September 23, 1998--Nitinol Medical Technologies, Inc.
(Nasdaq/NMI:NMTI) today announced the appointment of William J. Knight, 49,
to the position of Vice President of Finance and Administration, Chief
Financial Officer. Knight succeeds Theodore I. Pincus, who has resigned to
pursue other business opportunities. Mr. Pincus will remain in a
transitional consulting role until the end of November.
Since August 1996, William J. Knight has been Vice President Administration
and Chief Financial Officer of Zoll Medical Corporation, a medical device
manufacturer with approximately $60 million of worldwide sales. From
September 1989 to February 1996, Mr. Knight was Vice President, Corporate
Controller of Analytical Technology, Inc., a $125 million manufacturer of
scientific instrumentation. Owned by E.M. Warburg Pincus & Co., Analytical
Technologies was acquired by ThermoElectron Corporation in December 1995.
Commenting on Mr. Knight's appointment, Thomas M. Tully, President and
Chief Executive Officer of Nitinol Medical Technologies, Inc. said, "We are
very pleased to have Bill Knight join us at this stage in the growth and
development of our company. He brings to us a great deal of experience in
the financial management of a global manufacturing and marketing
organization. Additionally, Bill has successfully integrated foreign and
domestic acquisitions at both Zoll and Analytical Technology."
Nitinol Medical Technologies, Inc. designs, develops and markets innovative
medical devices that utilize advanced technologies and are delivered by
minimally invasive procedures. The Company's products are designed to offer
alternative approaches to existing complex treatments,
<PAGE>
thereby reducing patient trauma, shortening procedure, hospitalization and
recovery times, and lowering overall treatment costs. The Company's
patented medical devices include self-expanding stents, vena cava filters
and septal repair devices. The NMT Neurosciences division serves the needs
of neurosurgeons with a range of products including cerebral spinal fluid
shunts, the Selector Ultrasonic Aspirator, Ruggles Surgical Instruments,
the Spetzler Titanium Aneurysm Clip, and endoscopes and instrumentation for
minimally invasive surgery.
To receive Nitinol's latest news release and other corporate documents via
FAX -- at no cost -- please dial 1-800-PRO-INFO. Enter Nitinol's symbol
NMTI.
This press release contains "forward-looking statements" within the meaning
---------------------------------------------------------------------------
of the Private Securities Litigation Reform Act of 1995. Such forward-
----------------------------------------------------------------------
looking statements involve known and unknown risks, uncertainties or other
--------------------------------------------------------------------------
factors which may cause actual results, performance or achievements of the
--------------------------------------------------------------------------
Company to be materially different from any future results, performance or
--------------------------------------------------------------------------
achievements expressed or implied by such forward-looking statements.
---------------------------------------------------------------------
Factors that might cause such a difference include, but are not limited to,
--------------------------------------------------------------------------
those discussed under the heading "Certain Factors That May Affect Future
-------------------------------------------------------------------------
Results" included in the Management's Discussion and Analysis of Financial
--------------------------------------------------------------------------
Condition and Results of Operations in the Company's Annual Report on Form
--------------------------------------------------------------------------
10-K for the year ended December 31, 1997.
------------------------------------------
